New blood test could sniff out stomach Cancer's secret return
NCT ID NCT07243015
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study is testing a new blood test to find tiny traces of stomach cancer that might be left behind after surgery. The goal is to catch a recurrence earlier than standard scans. Researchers will collect blood samples from 500 people who had their stomach cancer removed and follow them over time to see if the test can predict when the cancer comes back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who underwent curative-intent gastrectomy for gastric adenocarcinoma, with available pre- and postoperative plasma samples.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically confirmed gastric adenocarcinoma. * Underwent curative-intent resection (R0). * Availability of pre- and postoperative plasma samples. * Documented clinical follow-up data (recurrence/metastasis status). * Provided written informed consent. Exclusion Criteria: * Insufficient plasma volume or RNA quality for exosomal extraction. * Presence of synchronous or metachronous malignancies. * Received neoadjuvant chemotherapy without postoperative follow-up. * Lack of consent or incomplete clinicopathologic data.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One small incision vs several: robotic stomach cancer surgery put to the test
- Can a personalized menu keep cancer patients stronger through chemotherapy?
- Can PET scans reveal which stomach cancers will respond to immunotherapy?
- Nerve-Block procedure tested against severe pancreatic and stomach cancer pain
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can a direct hit to tumors make immunotherapy work better?